670 related articles for article (PubMed ID: 19102665)
1. Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness.
Keith S
Expert Rev Neurother; 2009 Jan; 9(1):9-31. PubMed ID: 19102665
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacoeconomic review of the use of injectable long-acting risperidone].
Bartkó G; Fehér L
Neuropsychopharmacol Hung; 2005 Dec; 7(4):199-207. PubMed ID: 16496485
[TBL] [Abstract][Full Text] [Related]
3. [The first long-acting atypical antipsychotic: new milestone in the treatment of schizophrenia].
Faludi G
Neuropsychopharmacol Hung; 2005 Mar; 7(1):22-7. PubMed ID: 16167464
[TBL] [Abstract][Full Text] [Related]
4. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
5. Challenges in the design and conduct of controlled clinical effectiveness trials in schizophrenia.
Rosenheck RA; Krystal JH; Lew R; Barnett PG; Thwin SS; Fiore L; Valley D; Huang GD; Neal C; Vertrees JE; Liang MH;
Clin Trials; 2011 Apr; 8(2):196-204. PubMed ID: 21270143
[TBL] [Abstract][Full Text] [Related]
6. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.
Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa A; Goldfinger SM
J Clin Psychiatry; 2009 Oct; 70(10):1397-406. PubMed ID: 19906343
[TBL] [Abstract][Full Text] [Related]
7. Clinical review of a long-acting, injectable formulation of risperidone.
Knox ED; Stimmel GL
Clin Ther; 2004 Dec; 26(12):1994-2002. PubMed ID: 15823763
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience and management considerations with long-acting risperidone.
Parellada E
Curr Med Res Opin; 2006 Feb; 22(2):241-55. PubMed ID: 16466596
[TBL] [Abstract][Full Text] [Related]
9. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies.
Kane JM
J Clin Psychiatry; 2003; 64 Suppl 16():34-40. PubMed ID: 14680417
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of long-acting risperidone in Sweden.
Hensen M; Heeg B; Löthgren M; van Hout B
Appl Health Econ Health Policy; 2010; 8(5):327-41. PubMed ID: 20804225
[TBL] [Abstract][Full Text] [Related]
11. Risperidone long-acting injection (RLAI): the 12-week efficacy and tolerability in Thai patients with chronic schizophrenia.
Arunpongpaisal S; Srisurapanont M; Kongsakon R; Kitiwattanagul K; Samanwongthai U
J Med Assoc Thai; 2010 Mar; 93(3):343-50. PubMed ID: 20420110
[TBL] [Abstract][Full Text] [Related]
12. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries.
Peuskens J; Olivares JM; Pecenak J; Tuma I; Bij de Weg H; Eriksson L; Resseler S; Akhras K; Jacobs A
Curr Med Res Opin; 2010 Mar; 26(3):501-9. PubMed ID: 20014981
[TBL] [Abstract][Full Text] [Related]
13. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
[TBL] [Abstract][Full Text] [Related]
14. The case for long-acting antipsychotic agents in the post-CATIE era.
Nasrallah HA
Acta Psychiatr Scand; 2007 Apr; 115(4):260-7. PubMed ID: 17355516
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders.
Parellada E; Kouniakis F; Siurkute A; Schreiner A; Don L
Int Clin Psychopharmacol; 2010 May; 25(3):149-54. PubMed ID: 20305567
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics.
Ereshefsky L; Mascarenas CA
J Clin Psychiatry; 2003; 64 Suppl 16():18-23. PubMed ID: 14680415
[TBL] [Abstract][Full Text] [Related]
17. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
Marinis TD; Saleem PT; Glue P; Arnoldussen WJ; Teijeiro R; Lex A; Latif MA; Medori R
Pharmacopsychiatry; 2007 Nov; 40(6):257-63. PubMed ID: 18030649
[TBL] [Abstract][Full Text] [Related]
18. Risperidone long-acting injectable (Risperdal Consta®) for maintenance treatment in patients with bipolar disorder.
Bobo WV; Shelton RC
Expert Rev Neurother; 2010 Nov; 10(11):1637-58. PubMed ID: 20977322
[TBL] [Abstract][Full Text] [Related]
19. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety.
Hawley C; Turner M; Latif MA; Curtis V; Saleem PT; Wilton K
Hum Psychopharmacol; 2010 Jan; 25(1):37-46. PubMed ID: 20041474
[TBL] [Abstract][Full Text] [Related]
20. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Int Clin Psychopharmacol; 2008 Nov; 23(6):325-31. PubMed ID: 18854720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
